Skip to Main Content

The Food and Drug Administration has halted a clinical trial involving a Duchenne muscular dystrophy gene therapy from Solid Biosciences after a patient suffered serious kidney and blood-related injuries, the company said Tuesday.

This is the third time that the Cambridge, Mass.-based Solid has run into a serious safety problem with its gene therapy, called SGT-001. The FDA placed similar clinical holds on the same clinical trial after each prior incident, but later allowed the company to proceed with patient dosing.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • I would like to be part of the HIV/AIDS treatment campaign. I would appreciate an update on new drugs discovery leading to the final cure of the pandemic. Trust you find the above in order, regards – Zanele

Comments are closed.